loading...| Preferred Name |
eltrombopag olamine |
|
| Synonyms |
SB-497115 |
|
| Definitions |
The orally active ethanolamine salt of eltrombopag, a small-molecule, nonpeptide thrombopoietin receptor agonist with megakaryopoiesis-stimulating activity. Eltrombopag binds to and stimulates the transmembrane domain of the platelet thrombopoietin receptor (TPO-R or CD110), a member of the hematopoietin receptor superfamily. Activation of TPO-R leads to the proliferation and differentiation of cells in the megakaryocytic lineage and an increase in platelet production. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C62501" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C62501" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000420847 |
|
| altLabel |
SB-497115 Promacta SB-497115-GR SB497115 SB 497115 |
|
| cui |
C2369319 C1880492 C1961144 C1831906 |
|
| DATE FIRST PUBLISHED |
2005-02-11 |
|
| Date last modified |
2016-04-25 |
|
| definition |
The orally active ethanolamine salt of eltrombopag, a small-molecule, nonpeptide thrombopoietin receptor agonist with megakaryopoiesis-stimulating activity. Eltrombopag binds to and stimulates the transmembrane domain of the platelet thrombopoietin receptor (TPO-R or CD110), a member of the hematopoietin receptor superfamily. Activation of TPO-R leads to the proliferation and differentiation of cells in the megakaryocytic lineage and an increase in platelet production. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C62501" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C62501" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C62501 |
|
| notation |
CDR0000420847 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
eltrombopag olamine |
|
| tui |
T109 T116 T121 |